YOLFTbeta
Annovis Bio Inc

Annovis Bio Inc

ANVS · NYSE · Healthcare / Biotechnology

0.9261USD+0.08 (+9.31%)

Price History

Full chart

Market Stats

Previous Close0.8472
Open0.885
Day Range0.8142 – 0.951
52-Week Range1.04 – 5.50
Volume2.16M
Market Cap55.91M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.75
Dividend Yield0.00%
Beta1.24
50-Day Avg1.61
200-Day Avg2.26

About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Maria L. Maccecchini Ph.D.
  • Employees7
  • Headquarters101 Lindenwood Drive, Malvern, PA, United States, 19355, USA
  • Websitehttps://www.annovisbio.com

Leadership

  • Dr. Maria L. Maccecchini Ph.D.Founder, Acting CFO, CEO, President & Executive Director · b. 1951
  • Dr. Cheng Fang Ph.D.Chief Scientific Officer
  • Ms. Eve M. Damiano M.S., RACSenior Vice President of Regulatory Operations
  • Mr. Blake Jensen M.B.A.Head of Quality
  • Ms. Hilda MaibachSenior Vice President of Statistics

Financials

Income Statement

Currency: USD2009-12-312010-12-312011-12-312012-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue15.72K7.17M0185.18K000000000
Growth (%)-+45511.64%-100.00%--100.00%--------
Cost of Revenue5.38K6.04M011.45K---------
Gross Profit10.34K1.13M0173.72K---------
Gross Margin65.79%15.79%-93.82%---------
Operating Expense365.23K2.42M1.77M1.95M---------
Operating Income-354.89K-1.29M-1.77M-1.77M-682.43K-713.94K-1.61M-6.64M-14.54M-25.51M-45.03M-26.69M-29.70M
Operating Margin-2258.00%-17.99%--958.07%---------
EBITDA-----682.43K-713.80K-791.00K-5.46M-14.50M-25.51M-56.20M-22.74M-28.85M
Net Income-369.58K-1.32M-4.73M-8.32M-682.35K-713.87K-991.00K-5.46M-14.49M-25.15M-56.20M-24.59M-28.85M
Net Income Margin-2351.46%-18.35%--4495.62%---------
R&D----273.37K111.61K776.26K3.05M8.48M16.52M38.79M20.00M25.22M
Interest Expense0000846640.93M47.23M13.34K182.71K-1.85M-
Interest Expense % of Total Revenue0.00%0.00%-0.00%---------

Balance Sheet

Currency: USD2009-12-312010-12-312011-12-312012-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.52M22.05M21.01M2.84M357.96K50.99K1.12M8.12M46.00M36.02M10.21M13.93M21.08M
Total Liabilities45.49K5.55M7.09M174.36K7.32M7.64M9.69M578.38K1.51M7.70M17.96M4.62M4.23M
Total Equity1.48M16.49M13.93M2.66M-6.97M-7.59M-8.58M7.54M44.49M28.32M-7.75M9.31M16.85M
Cash31.76K4.40M1.39M72.32K347.47K35.31K1.86K8.07M45.69M28.38M5.75M10.55M19.53M
Total Debt------499.81K------
Net Debt-----347.47K-35.31K497.95K-8.07M-45.69M-28.38M-5.75M-10.55M-19.53M

Cash Flow

Currency: USD2009-12-312010-12-312011-12-312012-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-389.23K-1.77M-3.01M-1.41M-537.48K-558.61K-476.54K-3.97M-9.13M-17.31M-39.97M-21.89M-25.62M
Investing Cash Flow-350.39K-1.02M-81.98K-81.98K---------
Financing Cash Flow424.19K6.59M177.71K177.71K332.50K246.45K443.09K12.04M46.74M4.61K17.34M26.69M34.60M
Capital Expenditure5.16K155.87K79.60K79.60K000304440
Free Cash Flow-----537.48K-558.61K-476.54K-3.97M-9.13M-17.31M-39.97M-21.89M-25.62M
FCF to OCF----100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateMay 15, 2019Jul 3, 2019Mar 25, 2020May 5, 2020Jul 29, 2020Nov 4, 2020Mar 3, 2021May 6, 2021Jul 28, 2021Nov 3, 2021Mar 2, 2022May 4, 2022Aug 8, 2022Nov 8, 2022Mar 1, 2023May 10, 2023Aug 14, 2023Nov 8, 2023Mar 29, 2024May 10, 2024Aug 14, 2024Nov 8, 2024Mar 21, 2025May 8, 2025Aug 12, 2025Nov 12, 2025Mar 23, 2026May 15, 2026Aug 14, 2026Nov 11, 2026
EPS Estimate0.000.000.00--0.15-0.15-0.16-0.46-0.37-0.44-0.25-0.67-0.71-1.01-1.05-0.59-1.14-1.09-1.30-0.84-0.67-0.60-0.20-0.80-0.39-0.37-0.31-0.35-0.44-0.30
EPS Actual-0.03-0.03-0.04-0.10-0.34-0.15-0.25-0.46-0.34-0.35-0.75-0.72-1.07-0.93-1.05-1.19-1.07-1.63-2.24-0.10-0.44-0.97-0.43-0.32-0.32-0.37-0.39-0.63-0.40-
Surprise-----126.67%0.00%-56.25%0.00%8.11%20.45%-200.00%-7.46%-50.70%7.92%0.00%-101.69%6.14%-49.54%-72.31%88.10%34.33%-61.67%-115.00%60.00%17.95%0.00%-25.81%-80.00%9.09%-
Timing--After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap55.91M
Enterprise Value35.47M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book25.18
EPS-1.75
Book Value-0.10
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-703.68%
Return on Assets-142.36%
Shares Outstanding42.68M
Shares Float35.32M
Beta1.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 10.50
  • Strong Buy
    2
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
27.86%
Insiders
11.79%
Retail / Other
60.35%

Top Institutional Holders

  • Empery Asset Management, LP
    2.40M5.64%
  • Tudor Investment Corp Et AL
    1.36M3.19%
  • Marshall Wace Asset Management Ltd
    1.19M2.79%
  • Vanguard Capital Management, LLC
    872.38K2.05%
  • Two Sigma Investments LLC
    579.57K1.36%
  • Renaissance Technologies Corp
    347.60K0.82%
  • Geode Capital Management, LLC
    247.51K0.58%
  • Citadel Advisors Llc
    243.68K0.57%
  • Susquehanna International Group, LLP
    218.34K0.51%
  • Northern Trust Corp
    141.73K0.33%
  • BlackRock Inc
    139.53K0.33%
  • Vanguard Fiduciary Trust Co
    132.04K0.31%
  • Quadrature Capital Limited
    90.88K0.21%
  • State Street Corp
    77.73K0.18%
  • Group One Trading, LLC
    69.66K0.16%
  • First National Trust Co
    60.00K0.14%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.22M4.48%
  • Fidelity Extended Market Index
    153.14K0.56%
  • iShares Micro-Cap ETF
    102.65K0.38%
  • Fidelity Series Total Market Index
    45.69K0.17%